Management of nonalcoholic steatohepatitis: an analytic review

Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver, which, although usually relatively mild, may in some cause fibrosis, cirrhosis, and premature death resulting from liver failure. Its prevalence is increasing, and it is probably underestimated as a cause for cirrhosis. The ne...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical gastroenterology Vol. 35; no. 3; p. 253
Main Authors Agrawal, Sanjay, Bonkovsky, Herbert L
Format Journal Article
LanguageEnglish
Published United States 01.09.2002
Subjects
Diabetes Mellitus - epidemiology
Fatty Liver - epidemiology
Fatty Liver - physiopathology
Fatty Liver - therapy
Hepatitis - epidemiology
Hepatitis - physiopathology
Hepatitis - therapy
Humans
Hyperinsulinism - epidemiology
Iron - therapeutic use
Leptin - physiology
Liver Transplantation
Risk Factors
Silymarin - therapeutic use
Triglycerides - blood
Tumor Necrosis Factor-alpha - therapeutic use
Ursodeoxycholic Acid - therapeutic use
Vitamin E - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Nonalcoholic steatohepatitis (NASH) is a metabolic disorder of the liver, which, although usually relatively mild, may in some cause fibrosis, cirrhosis, and premature death resulting from liver failure. Its prevalence is increasing, and it is probably underestimated as a cause for cirrhosis. The need for an effective treatment is clear and urgent. Although several small, pilot, and randomized studies have been reported, large-scale studies are yet to be performed in patients with NASH. The aim of therapy is to intervene early in patients at risk of progression of liver disease. In this review, we summarize the extant literature on the management of NASH and discuss the potential future therapies and prophylactic recommendations in patients with NASH.
ISSN:0192-0790
DOI:10.1097/00004836-200209000-00011